Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11439832 | 0.89 | HRH3 (0.49) | PPARAHRH3ALDH1A1SLC13A5KCNH2 | |
| SCHEMBL992215 | 0.87 | PPARA (0.57) | PPARACYP4A11CYP4F2HRH3CA2 | |
| SCHEMBL1051632 | 0.86 | ALDH1A1 (0.59) | ALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL28340064 | 0.86 | PPARA (0.56) | PPARACYP4A11CYP4F2HRH3CA2 | |
| SCHEMBL8587467 | 0.84 | ALDH1A1 (0.58) | HRH3ALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL24171971 | 0.82 | CYP4A11 (0.58) | PPARACYP4A11CYP4F2CA2ALDH1A1 | |
| SCHEMBL8582205 | 0.80 | CYP4A11 (0.49) | PPARACYP4A11CYP4F2CA2ALDH1A1 | |
| SCHEMBL6025925 | 0.80 | KCNH2 (0.61) | PPARACYP4A11CYP4F2CA2SLC13A5 | |
| SCHEMBL55105 | 0.80 | PPARA (0.55) | PPARAHRH3SLC13A5 | |
| SCHEMBL25541204 | 0.79 | MAPT (0.52) | PPARACYP4A11CYP4F2HRH3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858798-B2 | metabolite of ebastine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20090137813-A1 | PROCESS FOR PRODUCTION OF CAREBASTINE | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-05-28 | — | — | US | claimed |
| CN-115427405-B | Tricyclic compounds, preparation method and medical application thereof | 合肥医工医药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137813-A1 | PROCESS FOR PRODUCTION OF CAREBASTINE | GABRE, GABRB3, GABRB2 | PPARA 3660/4885CYP4A11 1460/4885CYP4F2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.